{"pub_date": "2016-06-06T00:00:00Z", "subsection_name": null, "lead_paragraph": "Women taking a drug known as an aromatase inhibitor for an additional five years lowered the risk of a new or returning cancer, researchers said.", "print_page": "3", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "POLLACK", "firstname": "Andrew", "role": "reported"}], "original": "By ANDREW POLLACK"}, "multimedia": [], "section_name": "Health", "headline": {"print_headline": "Longer Use of Drug May Aid Breast Cancer Patients", "main": "Extending Estrogen Suppressor May Aid Breast Cancer Patients, Study Says"}, "source": "The New York Times", "blog": [], "word_count": "954", "web_url": "http://www.nytimes.com/2016/06/06/health/extending-estrogen-suppressor-may-aid-breast-cancer-patients-study-says.html", "slideshow_credits": null, "news_desk": "National", "type_of_material": "News", "snippet": "Women taking a drug known as an aromatase inhibitor for an additional five years lowered the risk of a new or returning cancer, researchers said.", "_id": "57540d4038f0d8278c72ea13", "abstract": "Researchers reporting in The New England Journal of Medicine say women with early-stage breast cancer could lower risks of disease returning by using estrogen-suppressing drug for 10 years instead of standard five.", "keywords": [{"rank": "1", "name": "subject", "value": "Breast Cancer", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y"}, {"rank": "3", "name": "organizations", "value": "New England Journal of Medicine", "is_major": "Y"}, {"rank": "5", "name": "subject", "value": "Estrogen", "is_major": "N"}]}